- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01332357
Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit
June 6, 2017 updated by: GlaxoSmithKline
The objective of this study is to compare readmission to the emergency department for asthma in asthma patients who receive treatment with fluticasone propionate and salmeterol oral inhaler after an initial emergency department visit using a retrospective observational cohort study design.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
6139
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
The study intends to identify subjects with asthma discharged from an emergency department that received fluticasone propionate/salmeterol from either an ED physician or from an outpatient physician
Description
Inclusion Criteria:
- Subjects with asthma as determined by ICD-9 codes and asthma drug use
- at least 12 years of age
- discharged from an initial Emergency Department visit within 12 months
Exclusion Criteria:
- Subjects with COPD or treatment for COPD
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Fluticasone propionate/salmeterol combination ED MD
Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician
|
Receipt of fluticasone propionate/salmeterol combination from the ED physician
|
Fluticasone propionate/salmeterol combination OP MD
Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician
|
Receipt of fluticasone propionate/salmeterol combination from the OP physician
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With an Asthma-related Event Occurring Between 1 and 6 Months Following the Index Event
Time Frame: Data were collected during a 4-year period from January 1, 2004 to December 31, 2008.
|
A subsequent asthma-related inpatient (IP) visit or emergency department (ED) visit were defined as visits within 6 months of the index event.
The index event was defined as an asthma-related hospitalization or ED visit occuring between 2004 and 2008.
|
Data were collected during a 4-year period from January 1, 2004 to December 31, 2008.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
July 1, 2010
Study Completion (Actual)
July 1, 2010
Study Registration Dates
First Submitted
April 7, 2011
First Submitted That Met QC Criteria
April 7, 2011
First Posted (Estimate)
April 11, 2011
Study Record Updates
Last Update Posted (Actual)
July 6, 2017
Last Update Submitted That Met QC Criteria
June 6, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease Attributes
- Emergencies
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenergic Agonists
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Sympathomimetics
- Fluticasone
- Xhance
- Salmeterol Xinafoate
- Fluticasone-Salmeterol Drug Combination
Other Study ID Numbers
- 112606
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Fluticasone propionate/salmeterol combination ED MD
-
GlaxoSmithKlineWithdrawnPulmonary Disease, Chronic Obstructive
-
GlaxoSmithKlineCompletedAsthmaUnited States, Argentina, Philippines, Canada, Brazil
-
GlaxoSmithKlineCompletedBronchial AsthmaJapan
-
Respirent Pharmaceuticals Co Ltd.Becro Ltd.Completed
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveRussian Federation, United States, Estonia, Chile
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveNetherlands
-
Mylan Pharma UK Ltd.Completed
-
Arthur F Gelb MDCompleted
-
Oriel TherapeuticsCompletedAsthmaUnited States